Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL.
Journal: Journal for immunotherapy of cancer
Published: August 22, 2025
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 06, 2022
Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Journal: Hematological oncology
Published: May 02, 2022
Clinical experience of CAR T cells for multiple myeloma.
Journal: Best practice & research. Clinical haematology
Published: August 03, 2021
Enhancing venetoclax activity in hematological malignancies.
Journal: Expert opinion on investigational drugs
Published: July 01, 2020
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 26, 2017
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
Journal: Haematologica
Published: May 14, 2016
Showing 1-7 of 7
Last Updated: 09/26/2026